Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT, Prevention
Conditions
Brief summary
Acute graft-versus-host disease (aGVHD) is a potentially fatal complication after allogeneic hematopoietic cell transplantation (HCT), particularly for that with a HLA-mismatched donor. Abatacept has been demonstrated as a potent drug to reduce the risk of aGVHD, but the efficacy of subcutaneous form has yet been investigated. This trial is designed to preliminarily determin the efficacy and saftey of subcutaneous abatacept in the prevention of aGVHD after haplo-identical HCT.
Interventions
DRUGAbatacept s.c.
subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age≧18 years 2. ECOG score 0-2 / Karnofsky score≧80 3. haplo-HCT is proposed 4. Conditioning with motified Bu/Cy+ATG regimen 5. Having the following hematologic malignancies with transplant indications: 1. Acute leukemia 2. Myelodysplastic syndrome 3. Aggressive lymphoma 6. Expected survival ≥ 3 months 7. Written informed Consent can be acquired 8. Agree to use effective contraception
Exclusion criteria
1. With a history of allo-HCT previously 2. Allergic/intolerant to Abatacept 3. Contraindications to the use of Abatacept 4. HIV infection, or active HBV infection or HCV infection 5. Uncontrolled active infection 6. Vital organ function intolerated to transplantation 7. Other malignancies except for the following diseases: malignant tumors that have been cured for at least 3 years without active lesions; adequete treated non-melanoma skin cancer, malignant amygdala, and carcinoma in situ without active lesions 8. Evidence of complications or medical conditions that may interfere with research or put the subjects at serious risk, including but not limited to severe cardiovascular disease (e.g. New York Heart Association grade III or IV heart disease, myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina) and/or severe lung disease (e.g. history of severe obstructive lung disease and symptomatic bronchospasm) 9. Pregnant and lactational women 10. Any life-threatening disease, medical condition, or organ dysfunction unfit for participants, or may interfere with the absorption or metabolism of Abatacept
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of overt aGVHD | 100 days post-HCT | The incidence of grade II-IV aGVHD post-transplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of aGVHD | 100 days post-HCT | The incidence of grade I-IV aGVHD post-transplantation |
| Incidence of severe aGVHD | 100 days post-HCT | The incidence of grade III-IV aGVHD post-transplantation |
| Early transplant-related mortality | 100 days post-HCT | The incidence of early transplant-related mortality |
| Relapse | 100 days post-HCT | The incidence of relapse/progression of underlying disease |
Countries
China
Outcome results
None listed